| 1 | Efgartigimod + Telitacicept (1-week interval) group | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [1] 11 11 💬
|
| 2 | Efgartigimod + Telitacicept (2-week interval) group | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [1] 11 11 💬
|
| 3 | Telitacicept | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [14] 11 11, 13, 14, 46, 48, 49, 51, 53, 63, 66, 162, 222, 223, 300 💬
|
| 4 | Telitacicept 160 mg | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [1] 53 53 💬
|
| 5 | Telitacicept 160mg | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [3] 49 49, 66, 223 💬
|
| 6 | Telitacicept 240mg | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [1] 66 66 💬
|
| 7 | Telitacicept 80 mg | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [1] 53 53 💬
|
| 8 | Telitacicept Freeze-dried powder Injection 80mg | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [1] 49 49 💬
|
| 9 | Telitacicept Tofacitinib | [2] Telitacicept Telitacicept (Telitacicept), Tofacitinib | [2] Tofacitinib citrate
Tofacitinib citrate
,
Tofacitinib
💬
| [4] JAK1 JAK1, JAK2, JAK3, TYK2 💬
| [39] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease, Efferocytosis, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 46 46 💬
|
| 10 | Telitacicept+SOC | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [1] 48 48 💬
|
| 11 | Telitacicept-only group | [1] Telitacicept Telitacicept (Telitacicept) | - | - | - | [1] 11 11 💬
|